Scouting report · HELP

#23Greg Cavers

CFO of Cybin/Helus Pharma since the November 2020 listing

Born / age
(56)
Role
Chief Financial Officer
In the role
6 yr
Education
CA (Chartered Accountant designation) Not stated
Front Office rank
#23 of 23
HELP
Cybin Inc.Biotech binary
Title
Chief Financial Officersrc
In role
since 2020-11 (6 yr)
Stake value$260k0.03% · 18,987 shares · as of 29 Jun 2026
D49 / 100

Scouting sheetas of 24 Sep 2026

Delivers guidance640 beat · 4 met · 0 missed · 1 withdrawn
Answers the question—no call reviewed yet
Capital allocation60company five-year record: neutral
Pay design10individual, time only · company lost money
Skin in the game33stake worth $260k, 0.2× last year's pay
80%Hit rate
—Pay at risk
—Say-on-pay
—Airtime on calls
Beat
0
Met
4
Missed
0
Withdrawn
1
Still open
2
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
Greg Cavers
Age
56src
Education
CA (Chartered Accountant designation), Not statedsrc

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
18,987 HELP, 2026-06-29src
Share of company
0.03%
Stake value
$260k
Stake ÷ pay
0.2× last year's pay
Last pay
$1.2m 2026src

What to weigh

Watch 2

  • Owns 18,987 shares (0.03%) excluding 83,334 unvested RSUs, the smallest direct stake of the listed officers, after almost six years as CFO; the company has no formal ownership guidelinesrc
  • Came from the CFO chair of a CSE-listed company under a cease-trade order for missed filings (LottoGopher); the order predates himsrc

In their favour 1

  • Continuity: the FY2026 CFO certification and the written milestone record in the dossier's S8 were signed under himsrc

Pay

Salary and otherBonus, stock, options, incentive

  • $632k2024
  • $1.2m2025
  • $1.2m2026
The table
YearSalaryBonusStockOptionsIncentiveOtherTotal
2024$197k$0$0$309k$126k$0$632ksrc
2025$350k$0$0$546k$301k$0$1.2msrc
2026$375k$0$598k$0$225k$19k$1.2msrc
Bonus pays on
Discretionary cash bonus against objectives the Compensation Committee sets each year; $225,000 paid for FY2026
Long-term award pays on
RSU grant ($598,000 in FY2026) with no performance condition disclosed; earlier years in optionssrc
  • Pay at risk not on file
  • Pays on returns individual, time only
  • Shareholder vote not on file
  • Pay vs profit company lost money

Career

  1. 2020-11 – now
    Cybin Inc. (Helus Pharma)src
    Chief Financial Officer
    Signed the 2021 Form 40-F registration as CFO (40FR12B-2021) and certifies the FY2026 annual filing (CERT-CFO-FY26); has served under every CEO and interim CEO since, from founding CEO Paul Glavine to Michael Halstead
  2. 2019-02 – 2020-01
    LottoGopher Holdings Inc. (CSE)src
    Chief Financial Officer and director (described in the AIF as interim CFO)
    End date January 2020 from AIF-FY26

Undated in the sources

  • CST Industries; Scotiabank; TD; CIBCsrc, VP Finance (CST Industries); Senior Manager Enterprise Functions (Scotiabank); Private Investment Advisor (TD); Retail Small Business Lending Controller and Director of Merchant Banking Finance (CIBC)

Not located: Everything before February 2019 is undated: the bank and CST Industries roles come only from a search summary of his own LinkedIn profile, and no Cybin filing read gives his pre-2020 career

The promise ledger5 scored · 2 open

ResultWhat was promisedWhere it is scoredHow
M MetRepay indebtedness — $22,765 out of the October 2025 offeringHELP row 1written outlook
M MetInitiate enrollment in EMBRACE — $1,196HELP row 2written outlook
M MetComplete the Phase 2 GAD study — $1,292HELP row 3written outlook
M MetProvide topline data from the Phase 2 GAD study — $810HELP row 4written outlook
W Withdrawn❗ HLP005 — deliver a drug development candidate by Q4 2026HELP row 5written outlook
· Still openAPPROACH topline efficacy readout in Q4 2026 (~$49,857 total, $23,686 remaining at 2026-03-31)HELP row 6written outlook
· Still openHLP004 — complete the design of the next study by the end of Q3 2026 (~$150, none spent at 2026-03-31)HELP row 7written outlook

Background

  • Regulatory Interim CFO of LottoGopher Holdings until January 2020; LottoGopher had been cease-traded on 2018-12-05 for failing to file interim financials, MD&A and certifications, before he took the rolesrc
  • Other Employment agreement gives 12 months' notice on termination without cause plus one month per completed year of servicesrc

Sources7